Addiction

Addiction is a chronic, relapsing disorder characterized by compulsive engagement with a substance or behaviour despite harmful consequences. The DSM-5-TR organizes addictive disorders by substance class (alcohol, cannabis, opioids, stimulants, etc.) plus gambling disorder, and the ICD-11 includes additional behavioural addictions including gaming and compulsive sexual behaviour.

Overview

Addiction is a chronic, relapsing condition characterized by compulsive engagement with a substance or behaviour despite negative consequences. Contemporary clinical frameworks recognize addiction as a brain disorder involving neuroplastic changes in reward, motivation, executive control, and stress regulation circuits — a substantial revision of older moral and willpower-based models.

The DSM-5-TR organizes addictive disorders into the chapter “Substance-Related and Addictive Disorders,” covering alcohol, cannabis, hallucinogens, inhalants, opioids, sedative-hypnotics, stimulants, tobacco, and other substances, plus gambling disorder as the only formally recognized behavioural addiction. The ICD-11 adds gaming disorder (6C51) and compulsive sexual behaviour disorder (6C72) as recognized addictive or impulse-control conditions.

Population prevalence is substantial. Lifetime prevalence of any substance use disorder in Canadian adults is approximately 20%; past-year alcohol use disorder approximately 5-7%; past-year cannabis use disorder approximately 2-3%. behavioural addictions (gambling, gaming, internet, sex) collectively affect another 2-5% of the population. Comorbidity with mood, anxiety, trauma, and other mental-health conditions is the rule rather than the exception.

Addiction develops through interaction of genetic vulnerability (heritability ~40-60% across substances), neurobiological susceptibility, developmental factors (early exposure, adverse childhood experiences), social and environmental context, and substance- or behaviour-specific characteristics (route of administration, speed of onset, accessibility, social acceptability). The “chronic disease” model — comparable to type 2 diabetes or cardiovascular disease in its biological, behavioural, and treatment dynamics — has supplanted older acute-illness or moral models.

Treatment is highly effective for most who engage. Evidence-based approaches include pharmacotherapy (medication-assisted treatment for alcohol, opioid, and tobacco use disorders has the strongest evidence), psychotherapy (CBT, motivational interviewing, contingency management, mindfulness-based relapse prevention), peer-support communities (12-step, SMART Recovery, refuge recovery), structural interventions (controlled-environment treatment for severe presentations), and integrated care for comorbid conditions. Recovery is the rule with sustained treatment, though relapse is common and frequently part of the recovery process.

Signs and symptoms

Loss of control — Use of the substance or behaviour in larger amounts or over a longer period than intended; repeated unsuccessful efforts to cut down or stop.
Time and effort — Significant time spent obtaining, using, or recovering from the substance or behaviour.
Craving — Persistent strong desire or urge to use the substance or engage in the behaviour.
Role obligation failure — Recurrent use resulting in failure to fulfill major obligations at work, school, or home.
Continued use despite social problems — Continued use despite persistent social or interpersonal problems caused or exacerbated by use.
Activities given up — Important social, occupational, or recreational activities given up or reduced.
Use in physically hazardous situations — Recurrent use in situations in which it is physically hazardous.
Continued use despite physical or psychological harm — Continued use despite knowledge of having a persistent or recurrent physical or psychological problem caused or exacerbated by the substance.
Tolerance — Need for markedly increased amounts to achieve the desired effect, or markedly diminished effect with continued use of the same amount.
Withdrawal — Characteristic substance-specific withdrawal syndrome on cessation, or use of the substance to relieve or avoid withdrawal symptoms.

Diagnostic context

The DSM-5-TR uses a unified diagnostic framework for substance use disorders. Each substance class (alcohol, cannabis, opioids, stimulants, etc.) has its own diagnostic code, but criteria are largely consistent: 11 criteria across four clusters (impaired control, social impairment, risky use, pharmacologic features), with severity specifiers based on number of criteria met (mild: 2-3, moderate: 4-5, severe: 6+).

Gambling Disorder (DSM-5-TR 312.31) is the only behavioural addiction in the DSM-5-TR addictive disorders chapter, with specific criteria (4+ of 9 features in 12 months).

The ICD-11 “Disorders Due to Addictive Behaviours” chapter includes Gambling Disorder (6C50), Gaming Disorder (6C51), and Compulsive Sexual Behaviour Disorder (6C72) as formally recognized behavioural addictions. Other proposed behavioural addictions (internet, shopping, exercise, food) are recognized clinically and in research but are not yet formal diagnoses.

Differential diagnosis includes:

Mood disorders with substance use (depression, bipolar disorder).
Anxiety disorders with substance use (PTSD, panic disorder, social anxiety).
Personality disorders (especially Cluster B).
ADHD (frequently underdiagnosed and contributing to substance use).
Medical conditions presenting with similar symptoms (delirium, dementia, endocrine disorders).

Validated assessment instruments include the AUDIT (alcohol), DAST (drug), CRAFFT (adolescent substance), DSM-5 Adult Self-Rated Substance Use Disorder Symptom Checklist, and structured clinical interviews. Toxicology testing is appropriate in many clinical contexts.

Causes and risk factors

Addiction develops through interaction of biological, psychological, and social factors:

Genetic factors: heritability of addictive disorders ranges from approximately 40% to 60% across substances and behaviors. Multiple common variants of small effect contribute, with substantial overlap across substance classes (general “addiction vulnerability”) and with comorbid conditions (depression, ADHD, schizophrenia).

Neurobiological factors: repeated substance use or addictive behaviour produces neuroplastic changes in the mesolimbic dopamine system (reward), prefrontal cortex (executive control), amygdala (stress and craving), and habenula (aversion processing). These changes persist long after acute use ends and contribute to vulnerability to relapse.

Developmental factors: early-life adversity (ACE exposure), early initiation of substance use (before age 15 substantially elevates lifetime risk), childhood ADHD or conduct problems, and family history of addiction all elevate risk.

Psychological factors: co-occurring mental-health conditions (depression, anxiety, PTSD, ADHD, personality disorders) substantially elevate risk and complicate treatment. Trauma exposure is particularly important.

Social and environmental factors: peer use, family use, accessibility, cultural acceptability, marketing exposure, neighbourhood disorder, poverty, and discrimination all influence both initiation and progression.

Substance-specific factors: route of administration (intravenous and inhaled produce faster onset and higher addiction risk than oral), pharmacokinetics (rapid-onset, short-acting substances are more addictive), social acceptability, legal status, and price all affect risk profile.

Comorbidity: approximately 50-60% of individuals with substance use disorders have at least one comorbid mental-health condition; the same is true in reverse. Integrated dual-diagnosis treatment produces better outcomes than sequential or parallel care.

Typical treatments

Treatment for addiction varies by substance, severity, comorbidities, and patient preferences. Evidence-based approaches include:

Pharmacotherapy / Medication-Assisted Treatment (MAT):

Alcohol Use Disorder: naltrexone (oral or extended-release injection), acamprosate, disulfiram, topiramate, gabapentin.
Opioid Use Disorder: methadone, buprenorphine (with or without naloxone), extended-release naltrexone. MAT is the standard of care; outcomes substantially exceed psychosocial treatment alone.
Tobacco Use Disorder: nicotine replacement therapy (patches, gum, lozenges, inhaler), varenicline, bupropion.
Stimulant Use Disorder: no FDA-approved medication; contingency management has the strongest evidence base.
Cannabis Use Disorder: no FDA-approved medication; CBT and contingency management are first-line.
Gambling Disorder: naltrexone has best evidence; nalmefene emerging.

Psychotherapy:

Cognitive behavioural Therapy — strong evidence across substances and behaviors.
Motivational Interviewing — useful entry-point intervention.
Contingency Management — among the strongest behavioural interventions, particularly for stimulants.
Mindfulness-Based Relapse Prevention.
Couples and family therapy.
Trauma-focused therapies for co-occurring PTSD.

Peer support and mutual aid: 12-step (Alcoholics Anonymous, Narcotics Anonymous, Gamblers Anonymous, etc.), SMART Recovery, Refuge Recovery, LifeRing — long-term participation is associated with better outcomes.

Levels of care: outpatient, intensive outpatient, partial hospitalization, residential, medical detoxification — matched to severity, support, and safety needs (ASAM criteria).

Integrated dual-diagnosis treatment: for individuals with co-occurring mental-health conditions, integrated treatment in a single program produces better outcomes than sequential or parallel care.

Harm reduction: naloxone distribution, supervised consumption sites, syringe services, drug-checking, and other harm-reduction interventions reduce mortality and disease transmission for individuals not yet engaging in abstinence-oriented treatment. Increasingly recognized as evidence-based component of comprehensive addiction care.

When to seek help

Professional support is indicated when:

You have been unable to control substance use or addictive behaviour despite repeated efforts to do so.
Use is producing significant consequences in relationships, work, finances, health, or legal status.
You experience cravings, tolerance, or withdrawal symptoms.
You are concealing the extent of use from family, partners, or healthcare providers.
Co-occurring depression, anxiety, PTSD, or other mental-health conditions are present.
You are using to manage emotions, cope with stress, or avoid withdrawal.
You are considering harm-reduction approaches (naloxone, drug-checking) or want to discuss alternatives to abstinence.

If you are experiencing an opioid overdose or witnessing one, contact emergency services (911) immediately and administer naloxone if available. Free 24-hour mental-health and crisis support is available across Canada at 9-8-8 (Suicide Crisis Helpline, call or text), 1-833-456-4566 (Talk Suicide Canada), or 811 (Health Link). For provincial addictions helplines: 1-866-332-2322 (Alberta Health Services Addiction Helpline, 24/7), 1-866-531-2600 (ConnexOntario, 24/7).

Frequently asked questions

Is addiction a disease or a choice?

Contemporary clinical frameworks recognize addiction as a chronic, relapsing brain disorder involving documented neurobiological changes — comparable in dynamic to other chronic diseases like type 2 diabetes. Initial use involves choice, but the development of addiction substantially impairs the same choice-making capacity. Treatment effectiveness reflects the disease model, not a moral failing.

Is medication-assisted treatment the same as substituting one addiction for another?

No. Medications used in MAT (methadone, buprenorphine, naltrexone, varenicline) are taken in stable, prescribed doses that do not produce intoxication, do not interfere with normal functioning, and substantially reduce mortality and use of the original substance. International medical consensus considers MAT the standard of care for opioid and other substance use disorders.

Do I have to go to AA or NA?

No. 12-step programs (AA, NA) work for many people but are not the only option. SMART Recovery, Refuge Recovery, LifeRing, and other peer-support frameworks have evidence and may fit better for some individuals. Many people use a combination of professional treatment and peer support; some recover without peer support.

Can I just cut down rather than quit completely?

For some substances and some severity levels, controlled or moderation-based approaches have evidence. For severe substance use disorder, opioid use disorder, and gambling disorder, abstinence-oriented approaches generally produce better outcomes. Decisions are individualized based on severity, substance, and personal goals.

Is relapse a sign of treatment failure?

No. Relapse rates in addiction (40-60% in the first year) are similar to those in other chronic diseases (hypertension, asthma, diabetes). Relapse typically reflects need for adjustment of treatment intensity or approach, not failure. Recovery is rarely linear; most people who achieve sustained recovery have one or more relapses along the way.

How long does treatment take?

Acute stabilization typically requires weeks to months. Sustained recovery is typically multi-year, often lifelong, with engagement intensity tapering over time. Maintenance treatment with medication is often appropriate long-term, particularly for opioid use disorder. Peer support is frequently lifelong.

References

American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). APA.
World Health Organization. (2022). International Classification of Diseases, Eleventh Revision (ICD-11). Disorders Due to Substance Use or Addictive Behaviours.
National Institute on Drug Abuse. (2018). Principles of Drug Addiction Treatment: A Research-Based Guide (3rd ed.).
American Society of Addiction Medicine. (2019). The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions (3rd ed.).
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363–371.

Find the pattern behind what's been feeling hard

A few simple questions to help surface the concerns that may fit best.

Find Your Pattern

Find a Therapist by City

Browse therapy availability by city to see local and virtual options, explore services, and connect with a clinician who can serve your area.

Addiction therapists in Calgary Addiction therapists in Edmonton Addiction therapists in Toronto Addiction therapists in Vancouver

Find a Therapist by Province

Browse therapy options by province to see which clinicians are available to work with clients in your region.

Addiction therapists in Alberta Addiction therapists in Ontario

Trusted by Leading Psychology & Mental Health Organizations Across Canada

ShiftGrit Psychology & Counselling is professionally regulated, certified, and recognized by leading psychology and mental-health organizations across Canada. These associations reflect our commitment to ethical practice, clinical standards, and evidence-informed therapy through Identity-Level Therapy and Reconditioning.

Trusted By Alberta’s Leading Psychology & Mental Health Organizations

ShiftGrit Psychology & Counselling is professionally regulated, certified, and recognized by leading psychology and mental-health organizations across Alberta and Canada. These associations reflect our commitment to ethical practice, clinical standards, and evidence-informed therapy through Identity-Level Therapy and Reconditioning.

Regulated and affiliated across Alberta’s leading psychology, counselling, and mental-health organizations.

Regulated and affiliated across Canada’s leading psychology, counselling, and mental-health organizations.

Authored by

ShiftGrit Clinical Editorial Team

The ShiftGrit Clinical Editorial Team combines the insight of registered psychologists, provisional psychologists, and trained writers to create accessible, evidence-informed therapy resources. All content is clinically reviewed by a Registered Psychologist.